drugset / Trial / NCT07405970
A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will evaluate the efficacy and safety of MIL62 compared with placebo in participants with systemic lupus erythematosus.
Timeline
- Start
- 2026-04-10
- Primary completion
- 2028-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MIL62 | Monoclonal antibody | 1000 mg | Intravenous |